Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

3 evidence topics · 2 sources

Summary: prevalence estimates

No identified publication reports the prevalence of RAF-altered pLGG requiring first-line systemic therapy. CBTRUS projects that 42,864 children and adolescents aged 0 to 19 years in the United States were living with a primary brain or other CNS tumor in 2025, including 21,591 with glioma and 9,193 with pilocytic astrocytoma; these figures exclude survivors who have reached adulthood. Day One Biopharmaceuticals reports a registry-based estimate (SEER and CBTRUS) of 26,000 patients under 25 years of age with BRAF-altered pLGG in the United States as of January 1, 2017, and an addressable pool of 2,000 to 3,000 patients per year with recurrent, progressive, or refractory pLGG at steady state.

United States: CBTRUS prevalence of pilocytic astrocytoma and glioma in ages 0 to 19 years

“An estimated 42,864 children and adolescents ages 0-19 years will be living with a primary brain or other CNS tumor diagnosis in 2025, making it the most prevalent tumor type in the age range.” (opens the source at this quote in a new tab)
“The histopathologic group with the highest prevalence was gliomas, with 21,591 cases.” (opens the source at this quote in a new tab)
“In 2025, the most prevalent histopathologic group is expected to be pilocytic astrocytoma (an estimated 9,193 cases).” (opens the source at this quote in a new tab)
“As these estimates include only children and adolescents 0-19 years of age at time of prevalence estimate, the total population of childhood and adolescent brain tumor survivors including those that are now in adulthood is significantly larger.” (opens the source at this quote in a new tab)

United States: company estimates of BRAF-altered pLGG prevalence and addressable population

“We partnered with an epidemiology firm to perform SEER and CBTRUS registry analysis that estimates the prevalence, as of January 1, 2017, in the United States for BRAF-altered patients with pLGG under the age of 25 to be 26,000. The estimated addressable pool of recurrent, progressive, or refractory patients with pLGG for tovorafenib is approximately between 2,000 to 3,000 per year at steady state.” (opens the source at this quote in a new tab)

Prevalence of RAF-altered pLGG requiring first-line systemic therapy

No evidence found.